1. Home
  2. IRIX vs SABS Comparison

IRIX vs SABS Comparison

Compare IRIX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRIX
  • SABS
  • Stock Information
  • Founded
  • IRIX 1989
  • SABS 2014
  • Country
  • IRIX United States
  • SABS United States
  • Employees
  • IRIX N/A
  • SABS N/A
  • Industry
  • IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRIX Health Care
  • SABS Health Care
  • Exchange
  • IRIX Nasdaq
  • SABS Nasdaq
  • Market Cap
  • IRIX 20.6M
  • SABS 19.0M
  • IPO Year
  • IRIX 1996
  • SABS N/A
  • Fundamental
  • Price
  • IRIX $1.03
  • SABS $1.25
  • Analyst Decision
  • IRIX Hold
  • SABS Strong Buy
  • Analyst Count
  • IRIX 1
  • SABS 5
  • Target Price
  • IRIX $2.00
  • SABS $11.40
  • AVG Volume (30 Days)
  • IRIX 142.5K
  • SABS 38.1K
  • Earning Date
  • IRIX 03-27-2025
  • SABS 05-19-2025
  • Dividend Yield
  • IRIX N/A
  • SABS N/A
  • EPS Growth
  • IRIX N/A
  • SABS N/A
  • EPS
  • IRIX N/A
  • SABS N/A
  • Revenue
  • IRIX $48,669,000.00
  • SABS $1,322,410.00
  • Revenue This Year
  • IRIX N/A
  • SABS N/A
  • Revenue Next Year
  • IRIX $5.44
  • SABS $25.00
  • P/E Ratio
  • IRIX N/A
  • SABS N/A
  • Revenue Growth
  • IRIX N/A
  • SABS N/A
  • 52 Week Low
  • IRIX $0.78
  • SABS $1.11
  • 52 Week High
  • IRIX $3.65
  • SABS $5.01
  • Technical
  • Relative Strength Index (RSI)
  • IRIX 45.12
  • SABS 31.17
  • Support Level
  • IRIX $0.78
  • SABS $1.11
  • Resistance Level
  • IRIX $1.07
  • SABS $1.80
  • Average True Range (ATR)
  • IRIX 0.12
  • SABS 0.16
  • MACD
  • IRIX 0.02
  • SABS -0.01
  • Stochastic Oscillator
  • IRIX 54.35
  • SABS 18.42

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: